152 related articles for article (PubMed ID: 19022512)
1. Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics.
Ríhová B; Kovár L; Kovár M; Hovorka O
Trends Biotechnol; 2009 Jan; 27(1):11-7. PubMed ID: 19022512
[TBL] [Abstract][Full Text] [Related]
2. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.
Duncan R; Vicent MJ; Greco F; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S189-99. PubMed ID: 16113096
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity.
Mrkvan T; Sirova M; Etrych T; Chytil P; Strohalm J; Plocova D; Ulbrich K; Rihova B
J Control Release; 2005 Dec; 110(1):119-29. PubMed ID: 16269198
[TBL] [Abstract][Full Text] [Related]
4. A new classification system of anticancer drugs - based on cell biological mechanisms.
Wu XZ
Med Hypotheses; 2006; 66(5):883-7. PubMed ID: 16414204
[TBL] [Abstract][Full Text] [Related]
5. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer.
Ayre SG; Garcia y Bellon DP; Garcia DP
Med Hypotheses; 2000 Oct; 55(4):330-4. PubMed ID: 11000062
[TBL] [Abstract][Full Text] [Related]
6. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulation in cancer therapeutics.
Ehrke MJ
Int Immunopharmacol; 2003 Aug; 3(8):1105-19. PubMed ID: 12860167
[TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations.
Lammers T
Adv Drug Deliv Rev; 2010 Feb; 62(2):203-30. PubMed ID: 19951732
[TBL] [Abstract][Full Text] [Related]
9. Locoregional treatment of malignant hepatic tumors with biologic response modifiers.
Yamamoto A; Sato T
Surg Oncol Clin N Am; 2008 Oct; 17(4):935-55, xii. PubMed ID: 18722927
[TBL] [Abstract][Full Text] [Related]
10. Novel cytotoxic drugs: old challenges, new solutions.
Ismael GF; Rosa DD; Mano MS; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):81-91. PubMed ID: 17905518
[TBL] [Abstract][Full Text] [Related]
11. Suppressive influences in the immune response to cancer.
Bronte V; Mocellin S
J Immunother; 2009 Jan; 32(1):1-11. PubMed ID: 19307988
[TBL] [Abstract][Full Text] [Related]
12. Exploring the role of polymeric conjugates toward anti-cancer drug delivery: Current trends and future projections.
Khan J; Alexander A; Ajazuddin ; Saraf S; Saraf S
Int J Pharm; 2018 Sep; 548(1):500-514. PubMed ID: 29964172
[TBL] [Abstract][Full Text] [Related]
13. Polymer conjugates as anticancer nanomedicines.
Duncan R
Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
[TBL] [Abstract][Full Text] [Related]
14. Antibody targeted drugs as cancer therapeutics.
Schrama D; Reisfeld RA; Becker JC
Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 21: combination strategies for cancer therapy.
Skak K; Kragh M; Hausman D; Smyth MJ; Sivakumar PV
Nat Rev Drug Discov; 2008 Mar; 7(3):231-40. PubMed ID: 18259184
[TBL] [Abstract][Full Text] [Related]
16. Potent antibody drug conjugates for cancer therapy.
Senter PD
Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies by modulating oxygen stress in cancer and inflammation.
Fang J; Seki T; Maeda H
Adv Drug Deliv Rev; 2009 Apr; 61(4):290-302. PubMed ID: 19249331
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound assistant chemotherapy may be a novel modality for solid tumors.
Pan H; Ma X; Li M; Chen J; Jiang H
Med Hypotheses; 2009 Oct; 73(4):526-7. PubMed ID: 19573996
[TBL] [Abstract][Full Text] [Related]
19. Novel antibodies as anticancer agents.
Zafir-Lavie I; Michaeli Y; Reiter Y
Oncogene; 2007 May; 26(25):3714-33. PubMed ID: 17530025
[TBL] [Abstract][Full Text] [Related]
20. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
